Clinical trial
A Prospective Multicenter Observational Study of the Safety and Effectiveness of Tenecteplase (rhTNK-tPA) for Acute Ischemic Stroke Across Different Transfer Pathways
NCT07897955 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started April 2027. Observational study, 2,000 participants (estimated). Lead sponsor Fujian Medical University Union Hospital; China. Primary measure: Modified Rankin Scale Score at 90 Days.
How it compares
768 similar trials: same condition (Ischemic Stroke) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Multicenter Observational Study of the Safety and Effectiveness of Tenecteplase (rhTNK-tPA) for Acute Ischemic Stroke Across Different Transfer Pathways
- Lead sponsor
- Fujian Medical University Union Hospital
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- April 1, 2027
- Completion date
- December 30, 2029
- Enrollment
- 2,000 (estimated)
- Sites
- 6
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: acute ischemic stroke
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Observational
- Sites
- 6
- Countries
- China
- Lead sponsor
- Fujian Medical University Union Hospital
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Patients Treated With Tenecteplase | tenecteplase | |
Show registry wordingPatients with acute ischemic stroke who receive intravenous tenecteplase as part of routine clinical care and are followed for 90 days. Treatment and transfer decisions are made by the treating physicians and are not assigned by the study protocol. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Modified Rankin Scale Score at 90 Days | 90 days after tenecteplase administration (±7 days) |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Tenecteplase
- US 5385732; expires June 2, 2014; assignee Genentech
Lead sponsor's other trials
Fujian Medical University Union Hospital, most recent start first.
+103 more trials
Similar trials
Same condition (Ischemic Stroke) and phase, most recent start first.
+763 more trials See the condition page